JPH02242160A - 血液中の脂質結合シアル酸含量の測定方法 - Google Patents
血液中の脂質結合シアル酸含量の測定方法Info
- Publication number
- JPH02242160A JPH02242160A JP1171347A JP17134789A JPH02242160A JP H02242160 A JPH02242160 A JP H02242160A JP 1171347 A JP1171347 A JP 1171347A JP 17134789 A JP17134789 A JP 17134789A JP H02242160 A JPH02242160 A JP H02242160A
- Authority
- JP
- Japan
- Prior art keywords
- sialic acid
- solution
- concentration
- lsa
- manganese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 title claims abstract description 39
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 title claims abstract description 38
- 210000004369 blood Anatomy 0.000 title claims description 15
- 239000008280 blood Substances 0.000 title claims description 15
- 238000005259 measurement Methods 0.000 title abstract description 35
- 210000002966 serum Anatomy 0.000 claims abstract description 29
- 150000002632 lipids Chemical class 0.000 claims abstract description 18
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960001755 resorcinol Drugs 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 102000004895 Lipoproteins Human genes 0.000 claims abstract description 7
- 108090001030 Lipoproteins Proteins 0.000 claims abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims abstract description 6
- 229920002307 Dextran Polymers 0.000 claims abstract description 3
- 238000000605 extraction Methods 0.000 claims abstract description 3
- 230000007935 neutral effect Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 35
- 239000002244 precipitate Substances 0.000 claims description 13
- 229910021380 Manganese Chloride Inorganic materials 0.000 claims description 9
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 9
- 239000011565 manganese chloride Substances 0.000 claims description 9
- 235000002867 manganese chloride Nutrition 0.000 claims description 9
- 239000007853 buffer solution Substances 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- 239000003791 organic solvent mixture Substances 0.000 claims description 4
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical class [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- -1 manganese (II) ions Chemical class 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 125000005629 sialic acid group Chemical group 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract description 6
- 229910001437 manganese ion Inorganic materials 0.000 abstract description 3
- 239000000872 buffer Substances 0.000 abstract description 2
- 150000003839 salts Chemical class 0.000 abstract description 2
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 abstract 3
- 238000004062 sedimentation Methods 0.000 abstract 2
- 238000007865 diluting Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000013049 sediment Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 35
- 238000012360 testing method Methods 0.000 description 35
- 201000011510 cancer Diseases 0.000 description 23
- 239000000523 sample Substances 0.000 description 20
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 239000012154 double-distilled water Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 230000003211 malignant effect Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 6
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000439 tumor marker Substances 0.000 description 6
- 238000005199 ultracentrifugation Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229960000633 dextran sulfate Drugs 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 150000002270 gangliosides Chemical class 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229940099607 manganese chloride Drugs 0.000 description 2
- MIVBAHRSNUNMPP-UHFFFAOYSA-N manganese(2+);dinitrate Chemical compound [Mn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MIVBAHRSNUNMPP-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 2
- 238000005375 photometry Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- KKADPXVIOXHVKN-UHFFFAOYSA-N 4-hydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C=C1 KKADPXVIOXHVKN-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 108010008629 CA-125 Antigen Proteins 0.000 description 1
- 102000007269 CA-125 Antigen Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 229910021568 Manganese(II) bromide Inorganic materials 0.000 description 1
- 229910021574 Manganese(II) iodide Inorganic materials 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000009388 chemical precipitation Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- RJYMRRJVDRJMJW-UHFFFAOYSA-L dibromomanganese Chemical compound Br[Mn]Br RJYMRRJVDRJMJW-UHFFFAOYSA-L 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical group [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- QWYFOIJABGVEFP-UHFFFAOYSA-L manganese(ii) iodide Chemical compound [Mn+2].[I-].[I-] QWYFOIJABGVEFP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU89885A HU204131B (en) | 1989-02-24 | 1989-02-24 | Method for detecting sial acidcontent adherent to the lipid of the blood |
| HU2251-885/89 | 1989-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02242160A true JPH02242160A (ja) | 1990-09-26 |
Family
ID=10951876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1171347A Pending JPH02242160A (ja) | 1989-02-24 | 1989-07-04 | 血液中の脂質結合シアル酸含量の測定方法 |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPH02242160A (hu) |
| KR (1) | KR920700401A (hu) |
| CN (1) | CN1045185A (hu) |
| AU (1) | AU3697189A (hu) |
| ES (1) | ES2013572A6 (hu) |
| HU (1) | HU204131B (hu) |
| WO (1) | WO1990010225A1 (hu) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5462877A (en) * | 1993-11-05 | 1995-10-31 | Katopodis; Nonda | Method for determining lipid bound sialic acid in plasma or serum |
| EP1002232A4 (en) * | 1997-07-15 | 2004-05-26 | Bioprobes Inc | DETERMINATION OF ALCOHOL CONSUMPTION USING SIALIC ACID / APO J |
| CA3125914A1 (en) * | 2019-01-07 | 2020-07-16 | 1866402 Ontario Limited | Blood separation and analysis device and methods |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342567A (en) * | 1981-07-06 | 1982-08-03 | Sloan Kettering Institute For Cancer Research | Sialic acid determination method |
| JPH0775557B2 (ja) * | 1986-04-25 | 1995-08-16 | 富士レビオ株式会社 | 脂質結合性シアル酸の測定法 |
-
1989
- 1989-02-24 HU HU89885A patent/HU204131B/hu not_active IP Right Cessation
- 1989-05-22 WO PCT/HU1989/000022 patent/WO1990010225A1/en unknown
- 1989-05-22 AU AU36971/89A patent/AU3697189A/en not_active Abandoned
- 1989-05-22 KR KR1019900702324A patent/KR920700401A/ko not_active Application Discontinuation
- 1989-06-21 ES ES8902167A patent/ES2013572A6/es not_active Expired - Fee Related
- 1989-06-27 CN CN89104231A patent/CN1045185A/zh active Pending
- 1989-07-04 JP JP1171347A patent/JPH02242160A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HU204131B (en) | 1991-11-28 |
| CN1045185A (zh) | 1990-09-05 |
| KR920700401A (ko) | 1992-02-19 |
| HUT53227A (en) | 1990-09-28 |
| AU3697189A (en) | 1990-09-26 |
| WO1990010225A1 (en) | 1990-09-07 |
| ES2013572A6 (es) | 1990-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0975973B1 (en) | Method for determining the presence of mutated brca protein | |
| US4039285A (en) | Single sample method for determination of lipoprotein concentrations in blood | |
| Burmester et al. | Evaluation of a rapid method for the determination of plasma fibrinogen | |
| Waalkes et al. | The determination of pentamidine (4, 4′-diamidinophenoxypentane) in plasma, urine, and tissues | |
| CN114032284A (zh) | 一种食管癌检测试剂及其在食管癌检测中的应用 | |
| Golde et al. | A blind comparison study of the lung phospholipid profile, fluorescence microviscosimetry, and the lecithin/sphingomyelin ratio | |
| US5045453A (en) | Method for determining sialic acid in plasma | |
| JP2020079729A (ja) | 尿中腫瘍マーカーによるがん検出方法、キット及び装置 | |
| CN103562726B (zh) | 用于非空腹的ldl胆固醇检测的体系和方法 | |
| JPH02242160A (ja) | 血液中の脂質結合シアル酸含量の測定方法 | |
| US5296346A (en) | Method for determining lipid bound sialic acid in plasma | |
| CN115728353A (zh) | MscCG在制备检测丙戊酸类药物的试剂盒中的应用 | |
| CN115327129A (zh) | 一种血浆分子标志物犬尿氨酸在早期心力衰竭检测中的应用 | |
| WO2005024423A2 (en) | A method for qualitative and/or quantitative detection of polyethylene glycols in biological fluids | |
| Toffaletti et al. | Spectrophotometric micro method for measurement of dialyzable calcium by use of cresolphthalein complexone and continuous-flow analysis. | |
| US4493898A (en) | Method for detecting and monitoring cancer | |
| JP3713901B2 (ja) | 破骨細胞由来酸性ホスファターゼの測定方法 | |
| US5462877A (en) | Method for determining lipid bound sialic acid in plasma or serum | |
| RU2504786C1 (ru) | Способ диагностики уролитиаза | |
| CN112730850B (zh) | 一种肾纤维化生物标志物及其应用 | |
| JP3547879B2 (ja) | フィブリノーゲン中のシアリル糖鎖による生化学検査方法およびフィブリノーゲンの精製方法 | |
| RU2754836C1 (ru) | Способ диагностики объемных образований головного мозга | |
| RU2827968C1 (ru) | Способ выявления рака легкого, рака предстательной железы, рака жкт у мужчин | |
| US7262058B2 (en) | Method for determining lipid associated sialoprotein in body fluids | |
| Abou Farha et al. | Urine laminin P1 assessment discriminates between invasive and noninvasive urothelial cell carcinoma of the bladder |